<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533832</url>
  </required_header>
  <id_info>
    <org_study_id>D02</org_study_id>
    <nct_id>NCT00533832</nct_id>
  </id_info>
  <brief_title>Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)</brief_title>
  <official_title>A Multicernter, Pivotal, Safety and Efficacy Study of the NeuroCtybernetic Prosthesis (NCP(R)) System in Patients With Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyberonics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyberonics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the safety and efficacy of the NCP System in treating patients in a nmajor&#xD;
      depressive episode.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients implanted with the vagus nerve stimulation (VNS) device and receiving VNS Intervention: vagus nerve stimulation (VNS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Implanted with vagus nerve stimulation (VNS) device, but not receiving VNS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>vagus nerve stimulation (VNS)</intervention_name>
    <description>intermittent vagus nerve stimulation&#xD;
Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. diagnosed with major depressive episode (MDE)&#xD;
&#xD;
          2. chronic (&gt;=2 years)or recurrent (&gt;-=4) lifetime MDEs&#xD;
&#xD;
          3. resistant to &gt;=2 treatments from different categories&#xD;
&#xD;
          4. completed &gt;=6 weeks of psychotherapy&#xD;
&#xD;
          5. score &gt;=20 on 24-item Hamilton Rating Scale of Depression&#xD;
&#xD;
          6. IQ &gt;=70&#xD;
&#xD;
          7. stable on current antidepressant medication (no more than 5 antidepressant meds) or&#xD;
             taking no antidepressant meds for &gt;=4 weeks before Visit B1&#xD;
&#xD;
          8. stable on atypical antipsychotic and anticonvulsant medications as for item #7&#xD;
&#xD;
          9. age &gt;=18 amd &lt;=80 years&#xD;
&#xD;
         10. male or nonpregnant female adequately protected from conception.&#xD;
&#xD;
         11. able to comply with testing and follow-up visits&#xD;
&#xD;
         12. voluntarily signed informed consent&#xD;
&#xD;
         13. patients with bipolar disorder demonstrated a resistance to lithium treatment or has a&#xD;
             medical contraindication to treatment with lithium or is known to be intolerant to&#xD;
             lithium (not applicable to patients with MDD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. atypical depression at study entry or psychotic symptoms in any MDE&#xD;
&#xD;
          2. history of schizophrenia, schizoaffective disorder, or delusional disorders&#xD;
&#xD;
          3. rapid cycling bopolar disorder&#xD;
&#xD;
          4. secondary diagnosis of, or signs of, delirium, dementia, amnestic, or other cognitive&#xD;
             disorders&#xD;
&#xD;
          5. failed 7 or more antidepressant treatments&#xD;
&#xD;
          6. a. suicide attempt requiring medical attention within previous 12 months b. &gt;=2&#xD;
             suicide attempts in the past 12 months c. cannot guarantee that will not implement&#xD;
             suicide d. likely to attempt suicide within next 6 mon in investigator's opinion&#xD;
&#xD;
          7. alcohol or substance dependence within previous 12 months or abuse within previous 6&#xD;
             mon other than nicotine dependence or abuse&#xD;
&#xD;
          8. history of myocardial infarction or cardiac arrest&#xD;
&#xD;
          9. other progressive neurological disease, significant central nervous system disease or&#xD;
             injury, or cervical fracture that makes implantation difficult&#xD;
&#xD;
         10. received general anesthesia with 390 days before enrollment.&#xD;
&#xD;
         11. taken an investigational drug within a clearance duration of 5 x the half-life of the&#xD;
             investigational drug or within &lt;=4weeks before Visit B1, whichever time is greater&#xD;
&#xD;
         12. enrolled in another investigational study&#xD;
&#xD;
         13. using another investigational device&#xD;
&#xD;
         14. significant cardiac or pulmonary condition currently under treatment resulting in an&#xD;
             ASA score &gt;=III&#xD;
&#xD;
         15. history of, or evidence of, significant brain malformation or significant head injury&#xD;
             or clinically apparent cerebral vascular events, or prior brain surgery such as&#xD;
             cingulatomy&#xD;
&#xD;
         16. unilateral or bilateral cervical vagotomy&#xD;
&#xD;
         17. demand cardiac pacemaker, implantable defibrillator, or other implantable stimulator&#xD;
&#xD;
         18. likely to require a whole body MRI after NCP implantation&#xD;
&#xD;
         19. currently receiving or likely to receive short-wave diathermy, microwave diathermy, or&#xD;
             therapeutic ultrasound diathermy after implantation&#xD;
&#xD;
         20. plans to relocate or move to a location distant from the study site within one year of&#xD;
             enrollment&#xD;
&#xD;
         21. previously enrolled in this or any other NCP System study -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Investigator</last_name>
    <role>Study Director</role>
    <affiliation>Cyberonics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, Howland R, Kling MA, Moreno F, Rittberg B, Dunner D, Schwartz T, Carpenter L, Burke M, Ninan P, Goodnick P. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005 Sep 1;58(5):364-73.</citation>
    <PMID>16139582</PMID>
  </results_reference>
  <results_reference>
    <citation>Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005 Sep 1;58(5):355-63.</citation>
    <PMID>16139581</PMID>
  </results_reference>
  <results_reference>
    <citation>Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005 Sep 1;58(5):347-54.</citation>
    <PMID>16139580</PMID>
  </results_reference>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <last_update_submitted>September 21, 2007</last_update_submitted>
  <last_update_submitted_qc>September 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2007</last_update_posted>
  <keyword>depression</keyword>
  <keyword>vagus nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

